First-line therapy with palbociclib in patients with advanced HR+/HER2− breast cancer: The real-life study PALBOSPAIN

zu Verbundenen Objekten

Standort
Deutsche Nationalbibliothek Frankfurt am Main
Umfang
1 Online-Ressource.
Sprache
Englisch

Erschienen in
First-line therapy with palbociclib in patients with advanced HR+/HER2− breast cancer: The real-life study PALBOSPAIN ; volume:206 ; number:2 ; day:1 ; month:4 ; year:2024 ; pages:317-328 ; date:7.2024
Breast cancer research and treatment ; 206, Heft 2 (1.4.2024), 317-328, 7.2024

Urheber
Martínez-Jañez, N.
Ezquerra, M. Bellet
Manso Sanchez, L. M.
Carrasco, F. Henao
Torres, A. Anton
Morales, S.
Ortega, P. Tolosa
Gil, V. L. Obadia
Sampedro, T.
Conejero, R. Andrés
Calvo-Martinez, L.
Galve-Calvo, E.
López, R.
Pena, F. Ayala de la
Lopez-Tarruella, S.
Araguiz, B. A. Hernando Fernandez de
Ruiz, L. Boronat
Cardenas, T. Martos
Chacon, J. I.
Antón, F. Moreno
Beteiligte Personen und Organisationen
SpringerLink (Online service)

DOI
10.1007/s10549-024-07287-w
URN
urn:nbn:de:101:1-2409110918059.762591826258
Rechteinformation
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
Letzte Aktualisierung
15.08.2025, 07:20 MESZ

Datenpartner

Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Original beim Datenpartner anzeigen

Beteiligte

  • Martínez-Jañez, N.
  • Ezquerra, M. Bellet
  • Manso Sanchez, L. M.
  • Carrasco, F. Henao
  • Torres, A. Anton
  • Morales, S.
  • Ortega, P. Tolosa
  • Gil, V. L. Obadia
  • Sampedro, T.
  • Conejero, R. Andrés
  • Calvo-Martinez, L.
  • Galve-Calvo, E.
  • López, R.
  • Pena, F. Ayala de la
  • Lopez-Tarruella, S.
  • Araguiz, B. A. Hernando Fernandez de
  • Ruiz, L. Boronat
  • Cardenas, T. Martos
  • Chacon, J. I.
  • Antón, F. Moreno
  • SpringerLink (Online service)

Ähnliche Objekte (12)

Overall survival in Japanese patients with ER+/HER2− advanced breast cancer treated with first-line palbociclib plus letrozole

Overall survival in Japanese patients with ER+/HER2− advanced breast cancer treated with first-line palbociclib plus letrozole

Real-world study of overall survival with palbociclib plus aromatase inhibitor in HR+/HER2− metastatic breast cancer

Real-world study of overall survival with palbociclib plus aromatase inhibitor in HR+/HER2− metastatic breast cancer

Palbociclib and letrozole for hormone receptor-positive HER2-negative breast cancer with residual disease after neoadjuvant chemotherapy

Palbociclib and letrozole for hormone receptor-positive HER2-negative breast cancer with residual disease after neoadjuvant chemotherapy

Comparative effectiveness of first-line palbociclib plus letrozole versus letrozole alone for HR+/HER2− metastatic breast cancer in US real-world clinical practice

Comparative effectiveness of first-line palbociclib plus letrozole versus letrozole alone for HR+/HER2− metastatic breast cancer in US real-world clinical practice

Palbociclib : im Fokus einer leitliniengerechten Therapie des Hormonrezeptorpositiven, HER2-negativen metastasierten Mammakarzinoms

Palbociclib : im Fokus einer leitliniengerechten Therapie des Hormonrezeptorpositiven, HER2-negativen metastasierten Mammakarzinoms

Comparative effectiveness analysis of survival with first-line palbociclib or ribociclib plus AI in HR + /HER2- advanced breast cancer (CEPRA study): preliminary analysis of real-world data from Thailand

Comparative effectiveness analysis of survival with first-line palbociclib or ribociclib plus AI in HR + /HER2- advanced breast cancer (CEPRA study): preliminary analysis of real-world data from Thailand

Outcomes of male patients with HR+/HER2– advanced breast cancer receiving palbociclib in the real-world POLARIS study

Outcomes of male patients with HR+/HER2– advanced breast cancer receiving palbociclib in the real-world POLARIS study

Palbociclib : CD4/6-Inhibition als Therapieoption bei Patientinnen mit fortgeschrittenem HR+/HER2-Mammakarzinom

Palbociclib : CD4/6-Inhibition als Therapieoption bei Patientinnen mit fortgeschrittenem HR+/HER2-Mammakarzinom

A phase 3 study (PATHWAY) of palbociclib plus tamoxifen in patients with HR-positive/HER2-negative advanced breast cancer

A phase 3 study (PATHWAY) of palbociclib plus tamoxifen in patients with HR-positive/HER2-negative advanced breast cancer

Real-World Tumor Response of Palbociclib in Combination With an Aromatase Inhibitor as First-Line Therapy in Pre/Perimenopausal Women With Metastatic Breast Cancer

Real-World Tumor Response of Palbociclib in Combination With an Aromatase Inhibitor as First-Line Therapy in Pre/Perimenopausal Women With Metastatic Breast Cancer

Neutropenia management with palbociclib in Japanese patients with advanced breast cancer

Neutropenia management with palbociclib in Japanese patients with advanced breast cancer

Overall survival results from the randomized phase 2 study of palbociclib in combination with letrozole versus letrozole alone for first-line treatment of ER+/HER2− advanced breast cancer (PALOMA-1, TRIO-18)

Overall survival results from the randomized phase 2 study of palbociclib in combination with letrozole versus letrozole alone for first-line treatment of ER+/HER2− advanced breast cancer (PALOMA-1, TRIO-18)

Verbundene Objekte